Earlier, the personalised "3S" paradigm of preclinical anticancer drug testing was developed in parallel with a new conception of predictive, preventive, and personalised medicine. The paradigm includes three main points: 1) Set of complementary mouse models to reproduce a wide range of human breast cancer (BC) types; 2) Steps of preclinical anti-cancer drug testing procedure starting from in vitro and in vivo research on transplanted and spontaneous BC mouse models followed by probing of preventive regimen(s); (3) Stratified sampling as a methodology to distinguish more homogeneous subgroups within a heterogeneous population of experimental inbred mice using maximal number of individual recipient characteristics before and after testing procedure. This personalised procedure permits revealing of both positive and negative effects of a given drug.
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Two types of different mouse models for preventive regimen testing exist within our paradigm; while commonly used preclinical drug testing procedures rarely include preventive regimen tests as one-level transplanted models are generally accepted. In contrast, our multistage conception proposes both transplanted and spontaneous BC mouse models using. The key advantage of a transplantable model is simultaneous developing of several homogenous populations of tumourbearing mice. However, this mouse model preserves well-known limitations as healthy young recipient mice do not reflect numerous main characteristics of cancer patients that are mostly aged having a number of concomitant chronic inflammatory diseases. Furthermore, autochthonous carcinogenesis in humans and mice is a multi-staged process that is characterised as gradual transformation of cells and evolutionary expansion of cell populations in situ; and immune system is supposed to play a key role in this process. Earlier, we showed that our non-SPF conventional mouse strains with high frequency of spontaneous BC in aged females with preceded inflammatory diseases mimic the human BC aetiology/morphology properly. Several studies of preventive regimen tests in both transplanted and precancerous spontaneous models are presented here to illustrate the acceptability of our paradigm. Firstly, a number of prestart transplanted mouse models of BC were used to test preventive regimens of immunotherapy by interleukin-2 and Imunofan ® . In majority of our experiments, a single application of immunostimulants 3 days before tumour cell inoculation resulted in significant stimulation of tumour appearance in treated male recipients. In parallel, pre-cancerous BLRB and CBRB aged females were used as spontaneous models to test preventive regimens of the same immunostimulants. In contrast with above-mentioned data, clear age-related inhibition of BC appearance in pre-cancerous treated groups was observed. Transplanted mouse models hardly may be considered as an adequate model to test preventive regimens of immunotherapy against BC; but this test is suggested to compare extent of efficacy of various immunostimulants. While prophylactic anti-cancer effect of used drugs was revealed in aged pre-cancerous females, obtained contradictory data warn against uncontrolled usage of immunostimulants in breast cancer prone population. In summary, our original anticancer drug methodology demonstrates practical and scientific applicability.
